INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass.
| Revenue (Most Recent Fiscal Year) | $25.38M |
| Net Income (Most Recent Fiscal Year) | $-169.93M |
| PE Ratio (Current Year Earnings Estimate) | 7.18 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.14 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -669.42% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -144.67% |
| Return on Assets (Trailing 12 Months) | -99.33% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.04 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.62 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.11 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.15 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.43 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.44 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 119.96M |
| Free Float | 89.49M |
| Market Capitalization | $77.51M |
| Average Volume (Last 20 Days) | 1.80M |
| Beta (Past 60 Months) | 0.40 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 25.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 70.36% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |